Wednesday, October 28, 2026
Data from SEC filings, checked daily
Public filings, plainly told
WallStPal · PDF guide
KURA Insider Trading: Buys and Sells by Kura Oncology, Inc. Insiders · https://wallstpal.com/stock/kura/insider-trading/ · saved 2026-10-28

About this page

Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.

How to read it

Form 4
The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
Buy (P) and Sell (S)
Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
Value
Shares times price, as reported on the filing.
10b5-1
A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
Late filing
A Form 4 filed more than two business days after the trade.
Vs. S&P 500
How the stock did after the trade minus how the overall market did in the same weeks.

A real example

In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.

Explain it like I'm 13

If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.

Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.

Summarize with AIChatGPTClaudePerplexityGoogle AIGrokCopilot
Insider tradingForm 4

Kura Oncology, Inc. (KURA) Insider Trading

13 open-market trades reported since Aug 17, 2026: 2 purchases worth $2.35M and 11 sales worth $1.71M.

By insider

InsiderRoleBuysBoughtSellsSoldLatest
Mollie LeoniChief Medical Officer0$02$440KSep 29, 2026
Brian T. PowlChief Commercial Officer0$03$397KSep 29, 2026
Teresa Brophy BairGeneral Counsel0$02$486KSep 29, 2026
Kathleen FordCOO0$02$112KSep 29, 2026
Thomas James DoyleSVP0$01$48KSep 29, 2026
Francis BurrowsChief Scientific Officer0$01$225KSep 25, 2026
Troy Edward WilsonCEO2$2.35M0$0Aug 24, 2026

All trades

KURA insider trades
FiledTradedInsiderRoleTypeSharesPrice ($)ValueHolding3 mo. afterFiling
Sep 29Sep 29Mollie LeoniChief Medical OfficerChief Medical Officer▼ SELL28,80210.75$310K−17%Form 4 ↗
Sep 29Sep 28Brian T. PowlChief Commercial OfficerChief Commercial Officer▼ SELL17,02010.53$179K−10%Form 4 ↗
Sep 29Sep 29Brian T. PowlChief Commercial OfficerChief Commercial Officer▼ SELL15,43010.75$166K−10%Form 4 ↗
Sep 29Sep 28Mollie LeoniChief Medical OfficerChief Medical Officer▼ SELL12,44810.50$131K−6.8%Form 4 ↗
Sep 29Sep 28Teresa Brophy BairGeneral CounselGeneral Counsel▼ SELL10b5-18,44210.50$89K−4.3%Form 4 ↗
Sep 29Sep 28Kathleen FordCOOCOO▼ SELL10b5-16,90610.50$72K−4.5%Form 4 ↗
Sep 29Sep 28Thomas James DoyleSVPSVP▼ SELL4,60710.50$48K−3.1%Form 4 ↗
Sep 29Sep 29Kathleen FordCOOCOO▼ SELL10b5-13,66810.75$39K−2.5%Form 4 ↗
Sep 25Sep 24Francis BurrowsChief Scientific OfficerChief Scientific Officer▼ SELL20,72610.83$225K−33%Form 4 ↗
Aug 24Aug 24Troy Edward WilsonCEOCEO (ind.)▲ BUY100,00012.39$1.24M+26%Form 4 ↗
Aug 24Aug 21Brian T. PowlChief Commercial OfficerChief Commercial Officer▼ SELL10b5-14,34511.89$52K−2.5%Form 4 ↗
Aug 21Aug 19Teresa Brophy BairGeneral CounselGeneral Counsel▼ SELL10b5-131,48712.63$398K−14%Form 4 ↗
Aug 17Aug 17Troy Edward WilsonCEOCEO (ind.)▲ BUY100,00011.12$1.11M+36%Form 4 ↗
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings